The hydrazone Schiff base analogues namely benzoic acid (4-allyloxy-benzylidene)-hydrazide and its series were designed and synthesized. The structures of newly synthesized compounds were characterized by analytical methods and spectral analysis and subjected to antibacterial and docking studies. The synthesized molecules were subjected to molecular docking studies using enoyl-acyl-carrier protein reductase (NADH) from mycobacterium tuberculosis as the receptor. The docking results confirm the binding affinity of the synthesized compounds with the selected receptor. Preliminary in-vitro anti bacterial studies were carried out with Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria. Benzoic acid (4-allyloxy-benzylidene)-hydrazide was found to be most potent anti tuberculosis agent at 200 and 100µg per ml, the percentage of inhibition was 98.7% and 97.9%. The designed synthesized molecules were considered for evaluation for the molecular docking studies of their binding pattern with enoyl-acyl-carrier protein reductase from Mycobacterium tuberculosis. The antimycobacterial screening was performed against MTB H37Rv an isoniazid-resistant clinical isolate of MTB was used for the study.
INTROdUCTION
Tuberculosis (TB) is a worldwide pandemic caused by different species of mycobacteria. Mycobacterium tuberculosis is a successful pathogen, which causes tuberculosis and is the greatest single infectious cause of death worldwide, killing approximately two million people annually 1 . Hydrazides are highly reactive bases with reducing properties. They have been used as a synthetic intermediate to produce different type of drugs in the treatment of different chronic illnesses. Hydrazides used in medicine include the anti-tuberculosis drug isoniazid and the antihypertensive and peripheral vasodilator drug hydralsane, whose hydrochloride is an effective drug for emergency reduction of blood pressure in hypertensive crisis. In the same way the hydrazine derivatives have been widely used in the treatment of tuberculosis and mental disorder. They can also be used as antimicrobial, antihypertensive, antimalarial and antitumoral agents [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Schiff bases are considered to be among the most important group of compounds in medicinal chemistry due to their preparative accessibility, structural variety and wide biological profile 12 . The synthesized benzohydrazides were potent antimicrobial and anticancer agents 13 . Numbers of hydrazide-hydrazone derivatives possess antituberculosis activity [14] [15] [16] [17] [18] [19] [20] [21] . The present study is aimed to carry out design, synthesis, in silico and in-vitro antimicrobial studies for the series of benzoic acid (4-allyloxy-benzylidene)-hydrazides.
ExpERIMENTAL
All the chemicals and solvents used are of analytical grade and were purchased from Royal scientific company and used without further purification. TlC was run on the silica coated aluminium sheets (TlC silica gel 60 F 254 , Analytical chromatography) and visualized in low UV light. IR spectra in kBr pellets were recorded on the FT-IR Perkin Elmer Spectrum spectrophotometer. 1 H NMR and C 13 NMR spectra were recorded on a 300 M Hz spectrometer with DMSO-d6 as solvent and TMS as internal reference. Chemical shifts are quoted as dppm and the coupling constants J in Hz in signals are described as s (singlet), d (doublet), t (triplet), m (multiplet) and b (broad). Melting points were determined on a Sigma melting point apparatus without corrections. GC MS mass spectrum was taken in JEOl GCMATE II GC-MS with Data system in a high resolution, double focusing instrument.
General procedure for the synthesis of benzohydrazides (3a-e)
The substituted benzoic acid (2.46 m mol) was refluxed with methanol in sulphuric acid for 4h. The ester formed reacts with hydrazine and gets converted to benzohydrazides by hydrozinolysis 22 .
Synthesis of benzoic acid (4-allyloxybenzylidene)-hydrazide (5a-e)
Benzaldehyde undergoes nucleophilic addition reaction with aromatic hydrazides resulting in the formation of hydrazones. The completion of reaction and the homogeneity of the synthesized compounds were checked by TlC. Further the product formed was washed with petroleum ether, dried, recrystallized and characterized by spectral analysis.
Ethanolic solution of 4-allyloxy benzaldehyde (10 m mol) was added to a 10 m mol of ethanolic solution of benzohydrazides and the reaction mixture was stirred for 30 minutes at room temperature in the presence of glacial acetic acid as catalyst. After refluxing for 3-5 h the completion of the reaction was monitored by TlC. The reaction mixture was cooled and placed in refrigerator overnight. The resulting solid was filtered and washed with petroleum ether and recrystallised with ethanol.
In silico Charaterisation
The synthesized compounds were assessed in silico for their biological activity using PASS server 23 . The three dimensional structure of the protein / enzymes was retrieved from Protein Data Bank 24 . The compound under study was docked with the identified receptor using Autodock 25 software and further analyzed for interactions using Pymol.
Antimicrobial activity
Antibacterial screening of the synthesized compounds was evaluated against Staphylococcus aureus and Escherichia coli, and the zone of inhibition was measured in mm. The broth media was inoculated and grown at 37ºC for 18 h to revive the bacteria from the stock cultures. The agar plates with wells were inoculated by spreading evenly with 18h old bacterial cultures (100 µl, 10-4 cfu). After 20 min, various concentrations of the compound and the antibiotic were filled in the wells. Finally, the plates were incubated at 37ºC for 24 h and the inhibition zone was observed 26 .
Luciferase reporter phage (LRp) assay (27)
The MTB H37Rv and clinical isolate of MTB were grown in Middlebrook 7H9 complete medium 12 with and without test sample for 3 days at 37°C. lRP assay was done using concentrations of 200, 100 and 50 µg/ml of test samples. 50µl bacterial suspension equivalent to MacFarlands. No.2 standard was added to 400 µl of 7H9 with and without the test compound. For each sample, two drug-free controls and two drug concentrations were prepared and this set up was incubated for 72 h at 37°C. After incubation, 50µl of the high titer luciferase reporter phage (phAETRC202) and 40 µl of 0.1 M CaCl 2 were added to all the vials and this set up was incubated at 37°C for 4 h. After incubation, 100 µl of the mixture was taken from each tube into a luminometer cuvette and an equal amount of working D-luciferin (0.3 mM in 0.05 M sodium citrate buffer, pH 4.5) solution was added. The Relative light Units (RlU) was measured after 10s of integration in the luminometer. Readings were recorded in duplicate for each sample and the mean was calculated. The percentage reduction in the RlU was calculated for each test sample and compared with that of control.
broth microdilution method
The MIC for MTB H37Rv and isoniazid (INH) resistant clinical isolate of MTB was determined using a broth microdilution method (28) in Middlebrook 7H9 medium supplemented with OADC, with a final inoculum of 1x10 7 cfu/ml. The compounds were dissolved in DMF (1.25 mg/ ml) and used as stock solution. Concentrations ranging from 1250 to 1 µg/ml were used to assess the effectiveness of the compounds. After inoculation the microtiter tubes were incubated at 37°C for 72 h, and the growth inhibition was recorded for 14 and 21 days, respectively. The MIC value represents the lowest dilution of the compound at which no bacterial growth was detected. 4-methoxy-benzoic acid (4-allyloxybenylidenehydrazide (5d) was prepared by the above mentioned method. 4-methoxy Synthesized compounds (Benzoic acid (4-allyloxy-benzylidene)-hydrazide), (4-chlorobenzoic acid (4-allyloxy-benzylidene)-hydrazide), were subjected to a preliminary anti bacterial screening against the strain gram positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria to assess the antibacterial susceptibility of the test compounds. The compounds showed good inhibition at lower concentration.
RESULTS
It is evident from table-1 that the compound 5a exhibits maximum anti-tuberculosis activity among all the study compounds as its probability of being active (Pa) value is 0.831 and Probability of being inactive (Pi) Synthesized compounds were evaluated for antimycobacterial activity using luciferase Reporter Phase (lRP) assay on MTB H37Rv and one isoniazid-resistant (INH-resistant) clinical isolate at National Institute for Research in Tuberculosis (NIRT), Chennai (28) .
The percentage growth inhibition was recorded at the concentrations of 200, 100 and 50 µg/ml (Table 3) . Seeing the good inhibition of the synthesized compound further biological assays were conducted to determine their MIC values on different strains of Mycobacterium.
Results of these investigations indicate that some of the test compounds exhibited significant antimycobacterial activity along with antibacterial activity against all the tested strains.
CONCLUSION
A series of hydrazone Schiff base analogues were synthesized in good yield adopting standard procedures. The compounds were REFERENCES characterized by spectral studies. Docking studies of the above mentioned compounds revealed scope for antibacterial activity especially anti-tuberculosis activity. Further, all the study compounds exhibit a binding better than the existing drug isoniazid for Tuberculosis. This was further confirmed using in vivo studies where compound 4-chloro-benzoic acid (4-allyloxy-benzylidene)-hydrazide had maximum inhibition (97.9%) 100µml. Hence, it can be concluded from the study that compound 4-chlorobenzoic acid (4-allyloxy-benzylidene)-hydrazide can be further evaluated for its efficiency in treating Tuberculosis.
